• Stryker Corporation has released its first-quarter 2026 results, reporting net sales of US$6,020 million and net income of US$745 million, with both basic and diluted earnings per share from continuing operations increasing compared with a year earlier.
• At the same time, Stryker is reshaping its business by combining its orthopaedic instruments portfolio with Mako and enabling technologies into a new Ortho Tech unit while reaffirming full-year 2026 guidance despite a recent cyber incident.
• Next, we’ll examine how maintaining 2026 guidance amid modest sales growth and the new Ortho Tech structure could influence Stryker’s investment narrative.

Uncover the next big thing with 23 elite penny stocks that balance risk and reward.

Stryker Investment Narrative Recap

To own Stryker, you generally need to believe in long term growth in surgical procedures and in the company’s ability to monetize its technology and implant portfolio. The latest quarter’s modest sales increase and reaffirmed 2026 guidance suggest the recent cyber incident has not materially altered the near term earnings catalyst, while existing risks around tariffs, regulatory approvals and supply chain still look more important to the story.

The creation of the new Ortho Tech unit, combining orthopaedic instruments with Mako and enabling technologies, is the announcement that ties closest to this quarter’s results. For investors focused on robotics and connected surgery as key growth drivers, this reorganization may clarify how Stryker plans to capture value from its innovation pipeline, even as cost pressures and reimbursement risks remain on the radar.

However, against this backdrop, tariff and supply chain pressures could still affect margins in ways investors should be aware of...

Stryker's narrative projects $32.0 billion revenue and $6.1 billion earnings by 2029.

Uncover how Stryker's forecasts yield a $419.11 fair value, a 33% upside to its current price.

Exploring Other Perspectives

Six members of the Simply Wall St Community currently value Stryker between US$340.49 and US$419.11 per share, underscoring how far opinions can spread. You can weigh those views against Stryker’s reaffirmed 2026 guidance and the new Ortho Tech structure to judge what the company’s growth potential could mean for future performance.

Explore 6 other fair value estimates on Stryker - why the stock might be worth as much as 33% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Stryker research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Stryker research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stryker's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.